Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
09/20/18 4:36 PM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Sep 19 2018
Summary ToggleAdverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD
- Sep 18 2018
Summary ToggleAdverum to Present at Cantor Global Healthcare Conference
- Aug 29 2018
Summary ToggleAdverum Biotechnologies Announces IND Active for ADVM-022, a Novel Gene Therapy to Treat Wet Age-related Macular Degeneration
- Aug 24 2018
Summary ToggleAdverum Biotechnologies Receives Orphan Drug Designation for ADVM-053, a Novel Gene Therapy Candidate for the Treatment of Hereditary Angioedema